ClinicalTrials.gg
WithdrawnNCT01587508Updated May 3, 2016

Study Comparing A New Drug Containing The Combination Meloxicam And Cyclobenzaprine In The Treatment Of Acute Lumbago

A Phase 3 interventional study of meloxicam/cyclobenzaprine hydrochloride and meloxicam - Movatec® in Acute Lumbago, sponsored by Eurofarma Laboratorios S.A.. Withdrawn at 11 sites in Brazil. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-05-03.

Sponsored by Eurofarma Laboratorios S.A. · Phase 3, Interventional, and Treatment

Why this study was withdrawn
The comparator product was withdrawn from the brazilian market not being possible to conduct the design regarding initially planned.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies in Low Back Pain with a site in Brazil — 10 open to participants now, 12 under way, none of them phase 3. Low Back Pain · Brazil.

Enrollment
119th of 122
0 · median 66
Started
2013
with 11 others
Phase 3
9 of 125
none open now
Registered
25th of 125
by date

Among the 125 studies in Low Back Pain with a site in Brazil, this one is the 119th largest by enrollment of the 122 interventional ones that give a count, is one of 12 that started in 2013, is one of 9 in phase 3, and was the 25th registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

10 of the 125 studies in Low Back Pain with a site in Brazil are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Low Back Pain with a site in Brazil, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy end tolerability of a new drug containing the combination meloxicam and cyclobenzaprine (7,5/10mg) and the same components alone in the treatment of acute lumbago.

Read the detailed description

To assess the efficacy and tolerability of a new drug containing the combination meloxicam and cyclobenzaprine in the treatment of acute lumbago, compared to the same components alone.

Some eligibility criteria:

Have a normal X-ray of the lumbar spine for the age; Have a baseline score in the VAS higher than or equal to 40 mm

03

Conditions studied

  • Acute Lumbago

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign, initial and date the Form (ICF);
  • Be between 18 and 75 years old;
  • Have acute lumbago with onset in less than 72 hours;
  • Have a normal X-ray;
  • Have a baseline score in the VAS higher than or equal to 40 mm;

Exclusion criteria

Exclusion Criteria:

  • Use of triptans;
  • Use of monoamine oxidase inhibitors;
  • Use of NSAIDs within the last week;
  • Previous use of narcotics;
  • Have any rheumatologic disease;
  • Conditions of chronic pain;
  • Have any significant chronic comorbidity;
  • Previous history of gastrointestinal bleed or ulcers;
  • History of allergy to any of the components of study medications;
  • Recent history of a myocardial infarction, cardiac arrhythmia, cardiac conduction block or change, or congestive heart failure;
  • Female patients who are pregnant or breastfeeding or who wish to become pregnant or who deny using safe methods during the study will not be enrolled in the study;
  • Have participated in another clinical trial within the last 12 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    meloxicam - Movatec®

    Drug: meloxicam - Movatec®

  • Active comparator
    cyclobenzaprine - Miosan®,

    Drug: cyclobenzaprine - Miosan®

  • Experimental
    meloxicam/cyclobenzaprine hydrochloride

    Drug: meloxicam/cyclobenzaprine hydrochloride

Interventions

  • Drugmeloxicam/cyclobenzaprine hydrochloride

    Drug pages: Meloxicam · Cyclobenzaprine

    two oral capsules a day during approximately 07 days

  • two oral tablet a day during approximately 07 days

  • Drugcyclobenzaprine - Miosan®

    two oral tablet a day during approximately 07 days

06

What researchers measure

Primary outcomes

  1. Pain Reduction

    Compare the treatment groups for the efficacy in pain reduction, 3 days after the administration of study drugs, when compared to the baseline assessment.

    Time frame: Pain reduction 3 days after the administration of study drugs

Secondary outcomes

  1. Frequency of rescue medication use

    Assessment of frequency of rescue medication use, as well as the proportion of patients during study treatment;

    Time frame: During study treatment, an expected average of 7days

07

Study locations

11 sites
  • Clínica de Ortopedia e Fraturas de Goiânia
    Goiania, GO, Brazil
  • CIP Pesquisas Médicas Ltda
    Goiânia -, GO, Brazil
  • Santa Casa de Misericórdia de Belo Horizonte
    Belo Horizonte, MG, Brazil
  • Santa Casa de Juíz de Fora
    Juiz de Fora, MG, Brazil
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, RS, Brazil
  • Faculdade de Medicina ABC
    Santo Andre,, SP, Brazil
  • Clinica de Ortopedia e Fisiatria Perdizes
    São Paulo, SP, Brazil
  • Hospital Santa Marcelina
    São Paulo, SP, Brazil
  • IMA Brasil
    São Paulo, SP, Brazil
  • Santa Casa de Votuporanga
    Votuporanga, SP, Brazil
  • Hospítal de Base
    São José Rio Preto, São Paulo, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2012
First posted
Apr 30, 2012
Start
May 2013
Primary completionActual
May 2013
CompletionActual
May 2013
Last update
May 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01587508
Responsible party
Sponsor
First posted
Apr 30, 2012
Start date
May 2013
Primary completion
May 2013
Completion
May 2013
Last update
May 3, 2016

Study contacts

Alceu Chueiri
principal investigator · Hospital de Base de São José do Rio Preto
Paulo Guilherme
principal investigator · Hospital Santa Marcelina
Wagner Caiafa
principal investigator · Santa Casa de Juiz de Fora
Antonio Scotton
principal investigator · Centro MIneiro de Pesquisa - Juiz de Fora
Lindomar G. Oliveira
principal investigator · Clínica de Ortopedia e Fraturas de Goiania
Antonio Carlos Ximenes
principal investigator · CIP Pesquisas Médicas Ltda
Sonia Alvarenga
principal investigator · Faculdade de Medicina ABC
Gilberto Brandão
principal investigator · Clínica Perdizes
Luciana Teixeira
principal investigator · IMA Brasil - Instituto de Medicina Avançada
Antonio Tarcísio
principal investigator · Santa Casa de Misericórdia de Belo Horizonte
Carlos Roberto Galia
principal investigator · Hospital de Clínicas de Porto Alegre
Mauro Hernandes
principal investigator · Santa Casa de Votuporanga

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Meloxicam · Cyclobenzaprine

Start the discussion